Clinical and haematological improvement induced by etidronate in a patient with idiopathic myelofibrosis and osteosclerosis

P. Sivera, L. Cesano, A. Guerrasio, C. Camaschella, U. Mazza

Research output: Contribution to journalArticlepeer-review

Abstract

We report a patient with agnogenic myeloid metaplasia associated with debilitating bone pain due to increased bone turnover and osteosclerosis. Treatment with etidronate at a dose of 6 mg/kg per day on alternate months resulted in a complete recovery of bone symptoms and normalization of metabolic parameters of bone turnover; unexpectedly, a sustained haematological improvement was also observed after several months of therapy, suggesting that bone marrow microenvironment improvement was able to restore a nearly normal haemopoiesis. We suggest that diphosphonate therapy may be of value in patients with AMM and increased bone turnover.

Original languageEnglish
Pages (from-to)397-398
Number of pages2
JournalBritish Journal of Haematology
Volume86
Issue number2
Publication statusPublished - 1994

Keywords

  • etidronate
  • myelofibrosis
  • osteosclerosis

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Clinical and haematological improvement induced by etidronate in a patient with idiopathic myelofibrosis and osteosclerosis'. Together they form a unique fingerprint.

Cite this